Source: Annual Congress 2003 - Lung cancer treatment
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
D. Antoniou, I. Karidis, G. Pavlakou, P. Mihalopoulou, D. Haimala, A. Tsimogiani, K. Papasarantopoulou (Athens, Greece). Does the incorporation of new generation cytotoxic agent improve the overall outcome in inoperable nonsmall cell lung cancer (NSCLC)?. Eur Respir J 2003; 22: Suppl. 45, 513

Member's Comments

No comment yet.

Related content which might interest you: The influence of secondary infectious process on non-small cell lung cancer (NSCLC) patients survival Source: Eur Respir J 2007; 30: Suppl. 51, 280s Year: 2007 Should patients with metastatic NSCLC and poor performance status be treated by chemotherapy? Source: Annual Congress 2007 - Treatment of metastatic nonsmall cell lung cancer in the era of targeted therapies Year: 2007 Trends in drug costs and overall survival in patients diagnosed with metastatic non-small cell lung cancer (NSCLC) Source: International Congress 2019 – How to guide patients to reach a balance between costs and personal needs: quality indicators of effectiveness Year: 2019 The treatment of stage IV non-small cell lung cancer with target therapies Source: Annual Congress 2013 –Which treatment other than chemotherapy for stage IV NSCLC? Year: 2013 Does long treatment delay affect survival in metastatic non-small cell lung cancer Source: Virtual Congress 2021 – Therapy of lung cancer Year: 2021 The method of individualisation of treatment and prognosis for advanced non-small cell lung cancer Source: Annual Congress 2010 - Prognostic factors for lung cancer Year: 2010 A novel biologic classification of non-small cell lung cancer Source: Annual Congress 2005 - New insights into prognosis in thoracic surgical oncology Year: 2005 Second line therapy for advanced non-small cell lung cancer Source: European Multidisciplinary Conference in Thoracic Oncology 2009 Year: 2009 Lung cancer: does age affect treatment strategy? Source: Eur Respir Mon; 2009: 43:306–326 Year: 2009 Role of chemotherapy in stage III non-small cell lung cancer (NSCLC): adjuvant or induction? Source: Annual Congress 2006 - Integrative approaches for stage III non-small cell lung cancer Year: 2006 Lung function evaluation in gemcitabine and concurrent radiotherapy treatment in nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 376s Year: 2001 Plasma DNA level in predicting therapeutic efficacy in advanced nonsmall cell lung cancer Source: Eur Respir J 2010; 36: 885-892 Year: 2010 Treatment tolerance and survival in elderly patients with stage IV non-small cell lung cancer (NSCLC) Source: International Congress 2019 – Symptoms, risks, complications and palliative care in thoracic oncology Year: 2019 Customising chemotherapy in advanced nonsmall cell lung cancer: daily practice and perspectives Source: Eur Respir Rev 2011; 20: 45-52 Year: 2011 Should there be a specific management for large cell neuroendocrine carcinoma? Source: Annual Congress 2005 - Neuroendocrine tumours of the lung Year: 2005 Analysis of the prognosis value of the mitochondrial activity in resected non-small cell lung cancer (NSCLC) Source: Annual Congress 2010 - Prognostic factors for lung cancer Year: 2010 24h-blood profile gene expression biomarkers of the response to bevacizumab-erlotinib (BE) in advanced non-squamous non-small cell lung cancer (NSCLC) Source: International Congress 2016 – Therapeutic trials in lung cancer Year: 2016 The role of palliative radiotherapy in locally advanced non small cell lung cancer Source: Annual Congress 2007 - Therapy of lung cancer Year: 2007 Selective adjuvant chemotherapy according to in-vitro chemoresistance test: Long term follow up of patients with resectable non-small cell lung cancer (NSCLC) stage IIIA Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010